Angiex
Angiex is a privately held, clinical-stage biopharmaceutical company developing first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumors, with lead asset AGX101 currently in a US Phase 1 trial.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Angiex does
Angiex is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts, developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for the treatment of solid tumors. Its proprietary Nuclear Delivery Platform exploits the TM4SF1 transmembrane protein's unique intracellular transport pathway — microdomain-enriched vesicles traveling along microtubules from the cell surface to the nucleus — to deliver chemotherapeutic payloads directly to the nuclei of tumor cells and tumor vascular endothelial cells. The lead asset, AGX101, is a TM4SF1-directed ADC with a maytansine-derived tubulin inhibitor payload conjugated via a hydrophilic linker; it is currently in a multi-site US Phase 1 dose-escalation and expansion trial (NCT06440005), with first patient dosed in August 2024. Preclinical data show picomolar IC50s, complete tumor regressions in xenograft models, and a claimed 10-fold improvement in therapeutic margin over Pfizer's earlier TM4SF1 ADC, with no observed overlap in toxicities with standard oncology drugs.
The company's technology targets solid tumors through three mechanisms: vascular injury (depriving tumors of blood supply), direct tumor cell killing of invasive and metastatic TM4SF1-positive cells, and immune activation via conversion of immunologically cold tumors to checkpoint inhibitor-responsive phenotypes. Angiex was founded by Harold Dvorak (discoverer of VEGF) and Shou-Ching Jaminet (discoverer of TM4SF1's role in angiogenesis) together with CEO-founder Paul Jaminet. The company is led by CEO Marty J. Duvall (joined 2022) with Iain Dukes as Executive Chairman, Glen Weiss as CMO, and Shou-Ching Jaminet as CSO. The current revenue model is pre-commercial; Angiex has indicated it may pursue a global pharmaceutical partnership for worldwide commercialization similar to the Daiichi Sankyo/AstraZeneca ADC model, while retaining clinical development and manufacturing internally. To date, the company has raised approximately $76M+ in equity financing, including a $45M Series B led by Presight Capital with Peter Thiel participation (Aug 2021) and a $31M financing completed in November 2025 with Paulson Investment Company as placement agent.
Angiex firmographics
Firmographics- Name
- Angiex
- Legal name
- Angiex Inc.
- Website
- https://angiex.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Angiex is a privately held, clinical-stage biopharmaceutical company developing first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumors, with lead asset AGX101 currently in a US Phase 1 trial.
- Ownership category
- akta.pro rank
Angiex industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
Keywords
Where Angiex is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Angiex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Biopharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. Angiex is developing AGX101 through Phase 1 clinical trials with the intent to commercialize the drug. The company has indicated it may pursue partnership with a global pharmaceutical company for marketing, sales, and distribution, similar to the Daiichi Sankyo/AstraZeneca model for ADCs, while retaining clinical development and manufacturing control internally.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Angiex product offering
Product offeringCore offering
Angiex develops first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumor oncology, with lead asset AGX101 (a TM4SF1-directed ADC) currently in Phase 1 clinical trials in the United States. The proprietary Nuclear Delivery Platform delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vasculature endothelial cells via the TM4SF1 transport pathway, enabling dual attack on tumor blood vessels and tumor cells with three mechanisms of action (vascular injury, direct tumor cell killing, immune activation).
Product overview
Angiex is developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. The company's lead product is AGX101, a first-in-class TM4SF1-directed ADC currently in Phase 1 clinical trials for solid tumors. AGX101 is built on Angiex's proprietary Nuclear Delivery Platform™ which exploits a novel TM4SF1 intracellular transport pathway to deliver payloads directly to the nucleus of tumor cells and tumor vasculature. The company also maintains a discovery-stage pipeline of additional ND-ADCs leveraging the same platform and target.
Differentiator
Problem solved
Functional benefit
Products and services
- AGX101 First-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) for the treatment of solid cancers. Currently in Phase 1 clinical trials. Attacks both tumor cells and tumor vasculature through three mechanisms: vascular injury to deprive tumors of blood supply, activation of anti-tumor immunity, and direct killing of invasive and metastatic tumor cells. Targets TM4SF1, which is highly expressed in tumor cells and tumor vascular endothelial cells but limited in normal adult tissue.
- Nuclear Delivery Platform Proprietary technology platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and endothelial cells of tumor blood vessels via TM4SF1's intracellular transport pathway. Enables creation of drugs for solid cancers with exceptional efficacy and therapeutic margin; protected by approximately a dozen patents on novel TM4SF1-directed ADC compositions and methods.
- TM4SF1-Targeted Discovery Pipeline Discovery-stage pipeline of additional Nuclear-Delivered Antibody-Drug Conjugates beyond AGX101, leveraging the same TM4SF1 target and Nuclear Delivery Platform for multiple solid tumor indications.
Quantifiable outcome
- Phase 1 dose-escalation and expansion trial initiated with first patient dosed August 7, 2024. Clinical site: NCT06440005 at multiple U.S. locations.
- +6 more outcomes
Companies that use Angiex
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Angiex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Angiex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- AbzenacoreAbzena, a global biopharmaceutical services provider and CDMO, provides critical clinical trial material manufacturing and bioconjugation services for Angiex's AGX101 Phase I clinical trial. Abzena's integrated services including cGMP manufacturing enabled Angiex to advance AGX101 into human trials. CEOs of both companies (Paul Jaminet of Angiex and Matthew Stober of Abzena) appeared jointly on the 'Chats with Chaudhrey' podcast discussing the collaboration.
- Millipore-Sigma (BioReliance End-to-End Solutions)coreMillipore-Sigma collaborated with Angiex in August 2017 to support clinical readiness of Angiex's lead oncology ADC candidate. This was the first project at Millipore-Sigma's Massachusetts BioReliance End-to-End Solutions center. The collaboration gave Angiex access to end-to-end process development tools, GMP manufacturing process development, education programs, and training. Angiex CEO Paul Jaminet cited Millipore-Sigma's broad process development capabilities as key to accelerating the path to clinic.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Angiex competitors and assessment
Company assessmentOthers
Direct peers
- Mersana Therapeutics: Clinical-stage ADC company developing next-generation ADCs for solid tumors using proprietary Dolasynthen and Immunosynthen platforms. Closely comparable to Angiex in modality, stage, and solid tumor focus.
Broad incumbents
- Daiichi Sankyo: Global ADC leader with Enhertu (DXd-ADC platform) partnered with AstraZeneca. Directly relevant as the model Angiex explicitly cites for its intended partnership/commercialization strategy and as the dominant player in solid-tumor ADCs.
- AstraZeneca: Co-developer of Enhertu and Datroway ADCs with Daiichi Sankyo; the reference commercial partner cited by Angiex. Comparable as a large-cap oncology company with a major ADC franchise in solid tumors.
- Pfizer: Major ADC player (Padcev) and historically developed a prior TM4SF1-directed ADC that AGX101 was designed to outperform by 10x in therapeutic margin. Highly relevant given direct prior work on the same target.
- Gilead Sciences (Immunomedics): Acquired Immunomedics to commercialize Trodelvy, a leading solid-tumor ADC. Comparable as a large oncology company with an ADC franchise overlapping Angiex's solid-tumor setting.
Emerging players
- Tubulis: Emerging clinical-stage ADC company developing differentiated solid-tumor ADCs using proprietary linker chemistries. Comparable in stage and technology-platform approach to Angiex.
- ProfoundBio: Clinical-stage ADC developer with multiple solid-tumor programs in Phase 1/2. Comparable in stage, modality, and solid tumor focus.
- Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing solid-tumor ADCs. Comparable as a similarly sized, similarly staged oncology biotech with platform-based ADC ambitions.
- CytomX Therapeutics: Clinical-stage oncology company using a Probody platform to develop masked ADCs and immunotherapies for solid tumors. Comparable in modality, stage, and platform-disciplined pipeline approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Angiex social profiles
Digital presenceAngiex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Angiex leadership team
Management profileNumber of profiles
Profiles5 records
Angiex funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Angiex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Angiex
What does Angiex do?
Angiex develops first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumor oncology, with lead asset AGX101 (a TM4SF1-directed ADC) currently in Phase 1 clinical trials in the United States. The proprietary Nuclear Delivery Platform delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vasculature endothelial cells via the TM4SF1 transport pathway, enabling dual attack on tumor blood vessels and tumor cells with three mechanisms of action (vascular injury, direct tumor cell killing, immune activation).
Is Angiex a public or private company?
Angiex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Angiex founded?
Angiex was founded in 2015. It employs 11 to 50 people.
Where is Angiex based?
Angiex is headquartered in Cambridge, United States, in the North America region.
How does Angiex make money?
One revenue line is on record: biopharmaceutical Development.
Who are Angiex's main competitors?
ImmunoGen (AbbVie) is listed as an others. Mersana Therapeutics is listed as a direct peer. Broad incumbents are Daiichi Sankyo, AstraZeneca, Pfizer and Gilead Sciences (Immunomedics). Emerging players are Tubulis, ProfoundBio, Pyxis Oncology and CytomX Therapeutics.
Does Angiex have an API?
No public API is recorded for Angiex.
What industry is Angiex in?
Angiex's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.